(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/113286 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 38/26* (2006.01)
A61K 9/08 (2006.01) *A61P 1/12* (2006.01)
A61K 47/14 (2017.01) *A61P 3/04* (2006.01)
A61K 47/18 (2017.01) *A61P 3/10* (2006.01)
A61K 47/26 (2006.01)

(21) International Application Number:
PCT/US2020/062785

(22) International Filing Date:
02 December 2020 (02.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1917723.7 04 December 2019 (04.12.2019) GB

(71) Applicant: **ROSE PHARMA LLC**; Clarendon House, 2 Church Street, Hamilton, HM11 (BM).

(72) Inventors; and
(71) Applicants: **KENNY, Enda** [IE/IE]; Metaphase Limited, 16 Rock Lodge, Killiney, Co., Dublin, A96C6K4 (IE). **WARBURG, Richard** [US/US]; 6501 Red Hook Plaza, Suite 201-998, St Thomas, USVI 00802 (VI).

(72) Inventors: **HAWE, Andrea**; Feilitzschstr. 32, 80802 München (DE). **KEILHAUER, Eva**; Pralat-Wellenhofer-Str. 25, 81377 München (DE). **POPKO, Olimpia**; Heiterwangerstr. 52, 81373 München (DE).

(74) Agent: **MAEBIUS, Stephen** et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2021/113286 A1

(54) Title: STABLE LIQUID FORMULATIONS COMPRISING A GLUCAGON-LIKE PEPTIDE 1 AND USES THEREOF

(57) Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.